Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances [0.03%]
心肌淀粉样变性的治疗策略：从机制发现到诊断和治疗进展
Ashley F Stein-Merlob,Rachel Swier,Darko Vucicevic
Ashley F Stein-Merlob
Diagnosis and treatment of cardiac amyloidosis have rapidly evolved over the past decade by harnessing mechanisms of disease pathogenesis. Cardiac amyloidosis is caused by myocardial deposition of fibrils formed by misfolded proteins, namel...
Darryl P Leong,Filipe Cirne,Jehonathan H Pinthus
Darryl P Leong
Cardiovascular disease is common in patients with prostate cancer and is an important cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practi...
Coralea Kappel,Robin Tumlinson,Susan Dent
Coralea Kappel
Improved screening and treatment have increased breast cancer survival rates, with over 7.8 million women surviving 5 years post-diagnosis globally. However, survivors face heightened cardiovascular morbidity and mortality due to cancer tre...
Ischemic Heart Disease in the Cancer Population: Trends, Outcomes, Epidemiology, and Challenges in Diagnosis and Treatment [0.03%]
癌症人群中的缺血性心脏病：趋势、结局、流行病学及诊断和治疗的挑战
Dorina-Gabriela Condurache,Zahra Raisi-Estabragh,Arjun K Ghosh et al.
Dorina-Gabriela Condurache et al.
Patients with cancer are at increased risk of ischemic heart disease (IHD). The increased risk of IHD in these patients is due to the interaction of shared risk factors, cancer type and stage, and immuno/chemotherapy and radiotherapy regime...
Arrhythmia Challenges in Cardio-Oncology: High-Risk Therapies, Management, and Anticoagulation [0.03%]
心脏肿瘤学中的心律失常挑战：高风险疗法、管理和抗凝治疗
Jonathan C Wright,Sneha Sharma,Adam S Potter
Jonathan C Wright
Cardiovascular disease and cancer are the leading cause of mortality in the United States. In 2021, there were 695,547 and 605,213 deaths due to heart disease and cancer, respectively. With novel oncologic and cardiac therapies, survival ha...
Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies [0.03%]
与癌症治疗相关高血压风险增加的抗肿瘤药物类型及管理策略
Hoda Sayegh,Alexia Zagouras,Joel W Neal et al.
Hoda Sayegh et al.
Hypertension (HTN) has been found to be the most common comorbidity in patients with cancer. In addition to increased prevalence of baseline HTN, patients with cancer may be at increased risk of HTN as a short-term or long-term adverse even...
Gentian Lluri,Prashanth Venkatesh
Gentian Lluri
Adults with congenital heart disease make up most patients with congenital heart disease vastly surpassing the pediatric patients largely because of significant improvements in the medical, interventional, and surgical approaches. An increa...
Michelle Weisfelner Bloom,Alana M Ferrari,Jadranka Stojanovska et al.
Michelle Weisfelner Bloom et al.
The organization of a cardio-oncology clinic and overall program is designed to provide comprehensive cardiovascular care to patients who are at risk of or have developed cardiovascular sequelae during or following cancer treatments. In thi...
Cardio-oncology Drug Interactions: A Primer for Clinicians on Select Cardiotoxic Oncologic Therapies [0.03%]
心血管肿瘤学药物相互作用——一些具有心脏毒性的抗肿瘤治疗药物的临床指南
Craig J Beavers,Alana M Ferrari
Craig J Beavers
Cardio-oncology is an emerging multidisciplinary field intended to mitigate and manage cardiovascular side effects and risks associated with cancer therapies. Clinician awareness of drug interaction management among cancer treatments, cardi...
Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy [0.03%]
免疫检查点抑制剂和嵌合抗原受体T细胞治疗相关的心脏并发症
Bhargav Makwana,Aishwarya Malode,Sumanth Khadke et al.
Bhargav Makwana et al.
Immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy have revolutionized cancer treatment but can cause life-threatening cardiovascular toxicities through immune-related adverse events. Myocarditis is the most common an...